Abstract
DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10-15 |
| Number of pages | 6 |
| Journal | Journal of managed care & specialty pharmacy |
| Volume | 25 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Pharmacy
- Pharmaceutical Science
- Health Policy
Cite this
The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis. / Mickle, Kristin; Lasser, Karen E.; Hoch, Jeffrey S; Cipriano, Lauren E.; Dreitlein, William B.; Pearson, Steven D.
In: Journal of managed care & specialty pharmacy, Vol. 25, No. 1, 01.01.2019, p. 10-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis
AU - Mickle, Kristin
AU - Lasser, Karen E.
AU - Hoch, Jeffrey S
AU - Cipriano, Lauren E.
AU - Dreitlein, William B.
AU - Pearson, Steven D.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.
AB - DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.
UR - http://www.scopus.com/inward/record.url?scp=85059239565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059239565&partnerID=8YFLogxK
U2 - 10.18553/jmcp.2019.25.1.010
DO - 10.18553/jmcp.2019.25.1.010
M3 - Article
VL - 25
SP - 10
EP - 15
JO - Journal of managed care & specialty pharmacy
JF - Journal of managed care & specialty pharmacy
SN - 2376-0540
IS - 1
ER -